[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355984-105":59,"doc-detail-355984-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nanoparticle-based-biomaterials-in-cancer-research-from-mechanistic-insights-to-therapeutic-innovation-review","Nanoparticle-Based Biomaterials in Cancer Research: From Mechanistic Insights to Therapeutic Innovation - review","","Cancer remains one of the most complex diseases to study and treat, with tumour microenvironment heterogeneity and therapeutic resistance limiting clinical progress. Biomaterials-based nanoparticles act as versatile platforms that advance cancer-biology understanding and enable innovative therapies. Mechanistically, they probe extracellular matrix interactions, mechanotransduction pathways, drug resistance, and tumour–immune crosstalk influenced by physical and biochemical cues. Therapeutically, engineered nanoparticles support targeted delivery of chemotherapeutics, nucleic acids, and immunomodulatory agents with stimuli-responsive release, multifunctionality, and theranostic features. Key challenges include biodistribution, safety, manufacturing scalability, and regulatory approval, while future precision nanomedicine is propelled by patient-derived models, high-throughput screening, and AI-assisted design.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanoparticle-based-biomaterials-in-cancer-research-from-mechanistic-insights-to-therapeutic-innovation-review/355984/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanoparticle-based-biomaterials-in-cancer-research-from-mechanistic-insights-to-therapeutic-innovation-review/355984.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How do nanoparticle-based biomaterials contribute to mechanistic cancer research?","Question",{"text":113,"@type":114},"They investigate extracellular matrix interactions, mechanotransduction pathways, drug resistance, and tumour–immune crosstalk to clarify how physical and biochemical cues shape disease progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What therapeutic functions do engineered nanoparticle systems provide?",{"text":118,"@type":114},"They enable targeted delivery of chemotherapeutics, nucleic acids, and immunomodulatory agents, incorporating stimuli-responsive release, multifunctionality, and theranostic capabilities.",{"name":120,"@type":111,"acceptedAnswer":121},"What main challenges limit clinical translation of nanoparticle therapeutics?",{"text":122,"@type":114},"Biodistribution, safety, manufacturing scalability, and regulatory approval are highlighted as ongoing barriers to progress from research to the clinic.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355984,1790194148,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Review  \nNanoparticle-Based Biomaterials in Cancer Research: From Mechanistic Insights to Therapeutic Innovation  \nManoochehr Rasekh 1,* and Sassan Hafizi 2  \nAcademic Editor: Calogero Fiorica  \nReceived: 25 May 2026  \nRevised: 22 June 2026  \nAccepted: 29 June 2026  \nPublished: 1 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 College of Engineering, Design and Physical Sciences, Brunel University of London, Uxbridge UB8 3PH, UK  \n2 School of Medicine, Pharmacy & Biomedical Sciences, University of Portsmouth, St. Michael’s Building, White Swan Road, Portsmouth PO1 2DT, UK  \n* [Correspondence: manoochehr.rasekh@brunel.ac.uk](Correspondence: manoochehr.rasekh@brunel.ac.uk)  \nAbstract  \nCancer remains one of the most complex diseases to study and treat, with tumour microenvironment heterogeneity and therapeutic resistance continuing to limit clinical progress. Biomaterials-based nanoparticles have emerged as versatile platforms that not only advance understanding of cancer biology but also enable innovative therapeutic strategies. As mechanistic tools, nanoparticles can be used to investigate extracellular matrix interactions, mechanotransduction pathways, drug resistance, and tumour–immune crosstalk, providing insights into how physical and biochemical cues influence disease progression. Therapeutically, engineered nanoparticle systems have been developed for the targeted delivery of chemotherapeutics, nucleic acids, and immunomodulatory agents, incorporating features such as stimuli-responsive release, multifunctionality, and theranostic capabilities. Recent advances in patient-derived tumour models, high-throughput screening platforms, and artificial intelligence-assisted design are further driving the development of precision nanomedicine. Despite ongoing challenges related to biodistribution, safety, manufacturing scalability, and regulatory approval, nanoparticle-based biomaterials offer significant opportunities to bridge fundamental cancer research and clinical translation. This review highlights recent mechanistic and therapeutic advances, discusses key translational barriers, and outlines future directions at the interface of biomaterials, nanotechnology, and oncology.  \nKeywords: cancer nanomedicine; biomaterials; nanoparticle drug delivery; tumour microenvironment; precision nanomedicine; cancer immunotherapy; stimuli-responsive nanoparticles; patient-derived organoids; artificial intelligence; theranostics  \n1. Introduction  \nCancer is a heterogeneous and dynamic disease driven not only by genetic and epigenetic alterations in malignant cells but also by complex interactions within the tumour microenvironment (TME) . The TME, comprising extracellular matrix (ECM), stromal and immune cells, vasculature, and soluble factors, shapes tumour progression, metastasis, and therapeutic response, and contributes to spatial and temporal heterogeneity that undermines treatment efficacy. The complexity is important because features such as ECM remodelling, hypoxic gradients, and immune suppression create physical and biochemical barriers to effective therapy and promote adaptive resistance [1–3] .  \nBiomaterials serve as dual-use platforms that both model these micro-environmental features in vitro and serve as engineered therapeutics in vivo. Engineered hydrogels, scaf-  \nfolds, and nanoparticle probes enable controlled presentation of matrix composition, stiffness, and soluble cues to dissect mechanotransduction pathways (for example, YAP/TAZ signalling) and cell–cell/cell–matrix crosstalk under defined, tunable conditions. In parallel, biomaterial-based formulations (from polymers and liposomes to inorganic nanomaterials) are used therapeutically to improve drug solubility, bio-distribution, tumour penetration, and controlled release, effectively translating","cbCail9gKclSVeeE","https://ap.wps.com/l/cbCail9gKclSVeeE","pdf",4367593,36,"English","# Introduction\n## Tumour microenvironment and therapeutic barriers\n## Biomaterials as dual-use platforms\n## Nanoparticles bridging biology and clinical translation\n# Abstract\n## Mechanistic insights\n## Therapeutic innovation\n## Translational challenges and future directions","[{\"question\":\"How do nanoparticle-based biomaterials contribute to mechanistic cancer research?\",\"answer\":\"They investigate extracellular matrix interactions, mechanotransduction pathways, drug resistance, and tumour–immune crosstalk to clarify how physical and biochemical cues shape disease progression.\"},{\"question\":\"What therapeutic functions do engineered nanoparticle systems provide?\",\"answer\":\"They enable targeted delivery of chemotherapeutics, nucleic acids, and immunomodulatory agents, incorporating stimuli-responsive release, multifunctionality, and theranostic capabilities.\"},{\"question\":\"What main challenges limit clinical translation of nanoparticle therapeutics?\",\"answer\":\"Biodistribution, safety, manufacturing scalability, and regulatory approval are highlighted as ongoing barriers to progress from research to the clinic.\"}]","Nanoparticle-Based Biomaterials in Cancer Research: From Mechanistic Insights to Therapeutic Innovation - review | PDF",1790122080,91,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/823196e2ba327d21b50232dcbdcfc0fb.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56bd792182e9468d715a31572dab040c.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4880e26e81c183d618c678c7610aba6b.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e468b61e42a0487eecbb07ae27a1e7b.webp",980,1385]